GlassScriptPhysician profile
Scott H Greenwald
NPI 1225007206
$1,604.37
in general payments reported to CMS, 2019-2025
20 companies · $16.02 in 2025
The $16.02 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $126 · 2021: $165 · 2022: $407 · 2023: $408 · 2024: $300 · 2025: $16.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $723.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $476.53 | 2021-2025 | Proclaim |
| Teva Pharmaceuticals USA, INC. | $163.16 | 2019-2023 | Ajovy, Austedo Xr |
| Abbvie INC. | $156.77 | 2022-2024 | |
| Amgen INC. | $117.32 | 2019-2022 | |
| Si-Bone, INC. | $98.47 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.28 | 2022 | |
| Pfizer INC. | $62.33 | 2019-2024 | |
| Lilly USA, LLC | $55.64 | 2020-2022 | |
| Nevro Corp. | $54.86 | 2021-2023 | Senza |
| Medtronic, INC. | $54.67 | 2022 | |
| Boston Scientific Corporation | $46.15 | 2020-2023 | Wavewriter Alpha Prime 16 |
| Novartis Pharmaceuticals Corporation | $43.36 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $43.16 | 2024 | Xtampza, Belbuca |
| Biodelivery Sciences International, INC. | $40.00 | 2019-2021 | |
| Medtronic USA, INC. | $26.79 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $25.96 | 2021 | |
| Supernus Pharmaceuticals, INC. | $20.74 | 2019 | |
| Grt US Holding, INC. | $19.20 | 2020 | |
| Assertio Therapeutics, INC. | $14.58 | 2019 | |
| Allergan, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Greenwald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.